SpicyIP

JANUARY 20, 2025

Deepak Gupta & Ors Do trade secrets/confidential information need to have economic or commercial value? And Ors on 10 January, 2025 (Delhi District Court) The Delhi District Court upheld the trademark rights of KRBL Ltd., Drop a comment below to let us know. Nirmala Agarwal Prop of Karmyogi vs B.C

Registering Trademarks 102

Registering Trademarks Trademark Registration IP 102

SpicyIP

FEBRUARY 23, 2025

A quick glance at last week – Madras HC accepts a US District Court’s Letter Rogatory to furnish confidential information, a look at Functional Fallacies in Thomson Reuters vs Ross Intelligence and many more. on 14 February, 2025, (Delhi HC) Manash Lifestyle Pvt. The deadline to file the comments is February 27.

Confidentiality 59

Confidentiality Trademark Copyright Infringement Music 59

SpicyIP

FEBRUARY 23, 2025

Softgel: The Errors of Comity The Madras High Court accepted a Letter Rogatory from The US District Court in Delaware directing India-based Softgel Healthcare to furnish confidential information to the US Court. on 14 February, 2025, (Delhi HC) Manash Lifestyle Pvt. Praharsh Gour writes on this order, highlighting the above omission.

Confidentiality 52

Confidentiality Trademark Copyright Infringement Music 52

LexBlog IP

AUGUST 16, 2023

On August 7, 2023, Formycon AG and Fresenius Kabi announced that they have reached a settlement with Johnson & Johnson (“J&J”) in the United States relating to FYB202, a proposed ustekinumab biosimilar to STELARA®, marketed by J&J. Economic terms of the settlement were not disclosed in the press release.

Settlement 52

Settlement Licensing Confidentiality Marketing 52

LexBlog IP

AUGUST 30, 2023

It has been reported that Celltrion has finalized a settlement with Johnson & Johnson (“J&J”) in the United States relating to CT-P43, Celltrion’s ustekinumab biosimilar to J&J’s STELARA®, which would permit Celltrion to launch the product in the U.S. market on March 7, 2025, if approved by FDA.

Settlement 40

Settlement Confidentiality Marketing Marketing 40

Bio Law Blog

JUNE 21, 2020

On May 28, Alexion and Amgen entered into a confidential settlement agreement to terminate the IPRs. Pursuant to the terms of the settlement agreement, effective March 1, 2025 (or earlier in certain circumstances), Alexion grants to Amgen a nonexclusive, royalty-free license under U.S. an eculizumab product.

Marketing 52

Marketing Marketing Settlement Patent 52

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 4, 2021

No earlier than July 31, 2023 per settlement. No earlier than November 20, 2023 per settlement. . No earlier than June 30, 2023 per settlement. No earlier than September 30, 2023 per settlement. No earlier than July 1, 2023 per settlement. No earlier than January 31, 2023 per settlement. January 2021.

Settlement 52

Settlement Litigation Marketing Marketing 52